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A large number of clinical measures of psoriasis are
used in clinical trials and daily practice. These
measures lack uniformity and validation. However,
valid outcome and severity measures for psoriasis are
a prerequisite for fully informative clinical research
and evidence-based medicine. The purpose of this
study was to identify all clinical measures of psoriasis
severity and outcome in use and to evaluate the
quality of these measures using clinimetric criteria;
we identified 53 separate clinical measures, which
were regrouped into 11 measures for quality analysis.
No measure could be scored on all items used in the
clinimetric analysis. The Lattice System Physician’s
Global Assessment and Physician’s Global Assessment
were most highly noted. We conclude that none of
the psoriasis measures is adequately validated.
The Psoriasis Area and Severity Index is the most
commonly used clinical measure in research, but
it has substantial limitations such as low response
distribution, no consensus on interpretability, and low
responsiveness in mild disease. Nevertheless, be-
cause of its widespread use the Psoriasis Area and
Severity Index permits some degree of comparison of
results among clinical trials. Overall, no best instru-
ment was identified, and different situations may call
for different measures.
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INTRODUCTION
To measure disease severity and effectiveness of therapies,
good clinical psoriasis measures are a necessity. For psoriasis,
the range of severity and outcome measures is extensive and
they lack uniformity and validation.
Psoriasis is a common disease with a high burden of
disease and substantial impact on quality of life (Krueger
et al., 2001). As there are no biomarkers available to assess
disease severity, clinical measures are used in clinical trials
and daily practice to measure severity and treatment
response. These measures are also used to categorize disease
severity and to allocate resources for instance considering
reimbursement criteria (NICE, 2006; www.labag.nl/info.htm).
A systematic review of clinical psoriasis measures in
randomized-controlled trials up to 2000, identified no less
than 44 different clinical measures used for psoriasis (Naldi
et al., 2003). Besides poor standardization of outcomes in
clinical trials, there is a lack of validation of the used measures.
Another review showed that no available measure fulfilled all
requirements of a validated instrument for disease assessment
(Ashcroft et al., 1999). Subsequent reviews concluded that there
is no ‘‘best’’’ outcome or severity measure for use in clinical
trials (Weisman et al., 2003; Feldman and Krueger, 2005).
The focus of severity measures is the discriminant ability
between severity levels of psoriasis, whereas outcome mea-
sures should be able to detect changes as a result of treatment.
Both types of measures must have the properties of validity and
reliability. The ideal measure is clearly defined with maximum
objectivity, universally applicable, is easy to use, flexible and
has clinical significance (Bigby and Gadenne, 1996; Jemec and
Wulf, 1997). The availability of such a measure seems utopian
and therefore it is necessary to know the quality and validity of
the existing clinical measures. This information is important
because consequential decisions are based on the scores of
these measures. Signaling imperfections of the measures may
lead to improved outcome and severity measures and as a
result in better decision making in patient care.
The aim of this systematic research was to update the list
of all clinical psoriasis measures and to evaluate their quality
in a clinimetric way.
RESULTS
Data synthesis
The two searches, designed to identify severity measures gave
807 hits (search 1) and 366 hits (search 2). Overall they
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yielded 53 different clinical psoriasis measures, which were
often similar and could be regrouped into 11 measures for
analysis (Table 1).
The search for articles regarding quality criteria of the
clinical psoriasis measures identified 6,815 articles of which
42 articles were included for data extraction based on the
inclusion and exclusion criteria.
Evaluation of the instruments
Table 2 gives an overview of the analyzed clinical psoriasis
measures. Table 3 presents the results of the clinimetric
evaluation. The available clinimetric data of each instrument
are described below:
Body surface area (BSA)
Many assessments of psoriasis severity incorporate an
estimation of involved BSA. Most commonly used to estimate
the BSA is the ‘‘rule of nines’’ (Ramsay and Lawrence, 1991).
It is defined as 9% coverage for the head and neck, each arm,
anterior and posterior leg as well as the four trunk quadrants
respectively, leaving 1% for the genitalia. The BSA can also
be estimated by the number of patients’ hand areas affected,
assuming that one ‘‘handprint’’ reflects approximately 1% of
BSA (Ramsay and Lawrence, 1991; Long et al., 1992;
Savolainen et al., 1997, 1998; Kreft et al., 2006; Thomas
and Finlay, 2007). Validity was only tested with the PGA,
which correlated strongly (Langley and Ellis, 2004). In
contrast to the varying inter-rater reliability, the intra-rater
reliability for area estimation was described as excellent
(Marks et al., 1989; Ramsay and Lawrence, 1991; Yune et al.,
2003).
The BSA was least improved after 2 weeks treatment
compared with other psoriasis parameters, which is negative
for responsiveness (Ormerod et al., 1997). Several scales are
in use, ordinal and continuous (Long et al., 1992; Feldman
et al., 1996; Harari et al., 2000; Gottlieb et al., 2003;
Jacobson and Kimball, 2004). The clinical assessed BSA did
not differ statistically from objectively assessed BSA, for
instance with computer-based image analysis in two studies
(Kanthraj et al., 1997; Ormerod et al., 1997). However,
several other studies showed that patients and clinicians
significantly overestimate the affected area, especially in mild
cases and when untrained (Ramsay and Lawrence, 1991;
Tiling-Grosse and Rees, 1993; Savolainen et al., 1997, 1998;
Yune et al., 2003; Kreft et al., 2006). The correlation
coefficient between BSA assessed by dermatologists and
patients ranged from r¼0.38–0.82 (Feldman et al., 1996,
2005; Fleischer, Jr et al., 1999; Szepietowski et al., 2001;
Sampogna et al., 2003).
Physical signs: erythema, scaling and induration
Plaque characteristics erythema, scaling and induration have
been widely used to evaluate psoriasis severity and remis-
sion. Validity for the sum of signs was only tested with the
PGA, correlation ran from r¼0.3 to r¼0.6 (Langley and
Ellis, 2004). Reliability and other criteria were not tested.
Many different scales were in use ranging from 2 to 8 points
(Serup and Agner, 1990; Lahti et al., 1993; Feldman et al.,
Table 1. All retrieved clinical outcome measures
re-grouped in 11 main clinical severity and outcome
measures for analysis
1. Psoriasis Area and Severity Index (PASI)
K Psoriasis Area and Severity Index (PASI)
K Extend Score of the Salford Psoriasis Index (SPI)
2. Body surface area (BSA)
K Body surface area (BSA)
K Total Body Surface Involvement
K Area Index (AI)
K Rule of Nines
3. Physician’s/Psoriasis Global Assessment (PGA)
Static assessment:
K Physician’s Global Assessment (PGA)
K Psoriasis Global Assessment (PGA)
K Investigator’s Global Assessment of Plaque Severity
K Investigator’s Global Severity Assessment of Psoriasis
K Investigator’s Global Assessment of Disease Severity
K Physicians’ Overall Assessment of the Extent of Psoriatic
Involvement
K Investigator’s Global Assessment of Overall Severity
K Overall Lesion Severity Scale (OLS)
K Physician Static Global Assessment
Dynamic assessment:
K Investigator’s Overall Response Assessment
K Investigator’s Assessment of Improvement
K Physicians’ Assessment of Clinical Response
K Investigator’s Global Assessment of Improvement form
baseline
K Clinical Response to Treatment
K Physician’s Global Assessment of Response to Treatment
K Overall Global Improvement of Psoriatic Lesions
K Physician’s Gross Assessment of Clinical Response
K Global Improvement Score
K Dynamic Global Assessment
4. Patient’s Global Assessment (PaGA)
Static assessment:
K Patient’s Global Assessment (PaGA)
K Patient’s Global Assessment of Plaque Severity
K Subject’s Global Severity Assessment of Psoriasis
K Patient’s Global Psoriasis Assessment (PGPA)
Table 1 continued on the following page
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1996; Ormerod et al., 1997; Harari et al., 2000; Gottlieb
et al., 2003). Erythema assessment is likely to be affected by
several factors including viewing geometry, ambient illumi-
nation, tanning of the surrounding skin, edema and the
experience and visual acuity of the observer (Lahti et al.,
1993). Varying correlations were found between clinical
assessment of erythema versus objective erythema apparatus
(r¼0.3–0.79) (Serup and Agner, 1990; Lahti et al., 1993;
Ormerod et al., 1997). The correlation coefficient between
erythema assessed by dermatologists and patients ranged was
moderate (r¼0.37–0.4) (Feldman et al., 1996; Fleischer, Jr
et al., 1999; Sampogna et al., 2003).
Patients rate degree of scaling as a strong indicator of
disease severity. However, application of moisturizers rapidly
affects scaling, making it an unstable parameter. Clinical
measurement of scaling correlated moderately to ultrasound
entry echo (r¼ 0.53) (Ormerod et al., 1997). Patient versus
dermatologist scaling assessment did not correlate (Fleischer, Jr
et al., 1999). Induration or thickness of psoriatic lesions is
probably the most specific parameter of psoriasis activity
(Gottlieb et al., 2003; Langley and Ellis, 2004). Elevation
correlated moderately to ultrasound thickness (r¼0.58)
(Ormerod et al., 1997). Patient versus dermatologist induration
assessment ranged from a weak correlation (r¼ 0.24)
to no correlation at all (Feldman et al., 1996; Fleischer, Jr
et al., 1999).
The Psoriasis Area and Severity Index (PASI)
In 1978, the PASI was developed to assess the effects of
retinoids in psoriasis (Fredriksson and Pettersson, 1979). The
affected area and lesion characteristics are entered in a
formula that results in a score from 0 to 72. PASI has been
criticized for being resource intensive, complex, lacking
sensitivity, low in accuracy and having a non-linear scale
(Harari et al., 2000; Berth-Jones et al., 2006). Nevertheless,
the PASI is often used as the standard measurement in
the validation of new measures and correlated well in most
cases with other physician-based assessments, but not with
HRQoL and symptoms measurements. Reliability was only
once correctly calculated (Berth-Jones et al., 2006). Response
distribution is low, because practically only half of the scale
is used (Fredriksson and Pettersson, 1978; Harari et al.,
2000; Jacobson and Kimball, 2004; Langley and Ellis, 2004;
Table 1. Continued
Dynamic assessment:
K Patient’s Overall Response Assessment
K Patient’s Global Assessment of Improvement
K Patient’s Assessment of Treatment Effect
K Patient’s Assessment of Clinical Response
K Patient’s Global Response to Treatment
5. Sum scores physical signs
K Psoriasis Severity Index/Scale
K Target lesion assessment/Score
K Local Psoriasis Severity Index of Target Lesions
K Target Area Score
K Target Plaque Severity Score
K Dermatological Sum Score
K Plaque Severity Score
K Total Sign Score (TSS)
K Plaque Modified Psoriasis Activity and Severity Index (PSI)
K Total Severity Score
K Plaque Severity Index
K Severity Index
K Psoriasis Grading Scale
6. Lattice-System Physician’s Global Assessment (LS-PGA)
7. Psoriasis Assessment Severity Score (PASS)
8. Simplified PASI (SPASI)
9. Psoriasis Exact Area and Severity Index (PEASI)
10. Psoriasis Long-based Area and Severity Index (PLASI)
11. Self-Administered PASI (SAPASI)
Initially retrieved clinical outcome measures, n=53.
Table 2. Overview of the 11 main clinical psoriasis
measures that were analyzed
Instrument Description
BSA Estimation of involved body surface area, several scores are
used
Signs Evaluation of the plaque characteristics erythema, scaling,
and induration. Erythema and scaling are easily influenced
by external factors
PASI The affected area and lesion characteristics are entered in a
formula that results in a score from 0 to 72. The PASI is most
often used in clinical trials
PGA The PGA is a 5, 6, or 7-point ordinal rating ranging from
‘‘clear’’ to ‘‘very severe psoriasis’’
PaGA The PaGA is an ordinal rating ranging from ‘‘clear’’ to ‘‘very
severe psoriasis’’ assessed by the patient
SAPASI The SAPASI is a structured PASI-like instrument designed for
patient self-assessments of severity
PASS The affected area and plaque characteristics are entered in a
formula that results in a score from 0 to 140. Infiltration is
given more weight than erythema and scaling.
LS-PGA The LS-PGA integrates ranges of involved BSA and the
overall plaque morphology in which infiltration is given
more weight
SPASI The SPASI equals the sum of the average redness, thickness,
and scaling of all the psoriasis lesions multiplied by the
percentage of body surface area involved
PEASI The PLASI is derived from the PASI but uses actual BSA
percentages instead of an area score
PLASI The PLASI is derived from the PASI but uses six BSA
groupings with finer partitioning for smaller extents of BSA
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Berth-Jones et al., 2006). PASI responsiveness is weak
when patients reach o10% BSA in any body area because
changes in the PASI entirely depend on plaque severity score
improvement and may underestimate the general degree of
improvement. PASI assessment gets more reliably by experi-
ence (Langley and Ellis, 2004). There is no consensus on the
interpretability (van de Kerkhof, 1992; Gottlieb et al., 2003;
Carlin et al., 2004; Jacobson and Kimball, 2004; Langley and
Ellis, 2004; Katz, 2005; Rapaport, 2005; Berth-Jones et al.,
2006). However, several proposals have been made, for
instance by Schmitt et al. who translated the PASI ranges
into the terms ‘‘mild’’, ‘‘moderate’’, and ‘‘severe’’ (Schmitt
and Wozel, 2005).
Physician’s Global Assessment (PGA)
Typically, the PGA is a 5, 6 or 7-point ordinal rating ranging
from ‘‘clear’’ to ‘‘very severe psoriasis’’. The PGA can be used
to show improvement by a comparison with baseline disease
severity (dynamic PGA) or it can be an assessment made at
one moment in time (static PGA). The PGA correlated well
with other clinically assessed, symptom and HRQoL psoriasis
measurements including the PASI (Gottlieb et al., 2003;
Langley and Ellis, 2004; Berth-Jones et al., 2006). The PGA
correlated more with BSA than with signs, although the extent
of involvement should not be incorporated in the PGA
(Langley and Ellis, 2004). Reliability was calculated to be
good and experience appeared to have a neglectable effect
on PGA assessment (Langley and Ellis, 2004). The scales are
clear and most of the scale is used (Gottlieb et al., 2003;
Berth-Jones et al., 2006).
Patient’s Global Assessment
No studies were identified assessing clinimetric properties of
the patient’s global assessment.
Self-Administered PASI (SAPASI)
The SAPASI is a structured PASI-like instrument designed for
patient self-assessments of severity (Fleischer, Jr et al., 1994).
Patients shade in affected areas on a silhouette of a body to
estimate body surface area and complete visual analog scales
for the extent of erythema, induration and scaling of their
‘‘average’’ lesion. The investigator uses these data and
combine them into a complex score, ranging from 0–72.
The SAPASI correlation with the PASI has been measured
many times and appeared to be strong in most cases
(Feldman et al., 1996, 2005; Kirby et al., 2000, 2001;
Szepietowski et al., 2001; Sampogna et al., 2003, 2004). The
SAPASI did not correlate well with HRQoL measurements
(Kirby et al., 2000; Sampogna et al., 2004). Reliability of
the SAPASI was described to be very good (Feldman et al.,
1996; Fleischer, Jr et al., 1996). The SAPASI was reported
to be responsive to changes in severity over time because
it correlated well with changes in PASI (r¼0.62), but
the responsiveness of the latter is doubtful (Feldman et al.,
2005). Psoriasis is defined as ‘‘in remission’’ when
SAPASI¼0, ‘‘mild’’ when 0 o SAPASI o 3, ‘‘moderate’’
when 3 o SAPASI o 15 and ‘‘severe’’ when SAPASI 415
(Fleischer Jr, et al., 1996).
Psoriasis Assessment Severity Score (PASS)
The PASS was developed to be simpler and faster than the
PASI (Harari et al., 2000). Overall evaluation is divided in
two stages: in the first the BSA is determined in percentage,
than the general erythema, desquamation and induration are
assessed on a three-point scale. Finally, the sign scores
together with the total percentage BSA are combined in a
complex formula, which gives an overall score between
0 and 140. In this calculation, infiltration is weighted more
heavily than erythema. Almost all patients are in the lower
half of the score. The PASS has not been validated. Inter-rater
reliability was described to be better than the PASI (Harari
et al., 2000).
Lattice System Physician’s Global Assessment (LS-PGA)
The LS-PGA is similar to the PGA, but takes a quantitative
approach to the global assessment of disease severity by
integrating ranges of involved BSA and the overall plaque
morphology (Langley and Ellis, 2004). The BSA percentage
involved is measured in categories of 0, 1–3, 4–9, 10–20,
21–29, 30–50 and 51–100%. The LS-PGA gives more weight
to induration compared with scaling and erythema. Validity
and reliability were shown to be very good. Psoriasis severity
is stratified in eight categories (clear to very severe) and most
of the scale was used (Berth-Jones et al., 2006). Although it
has been suggested that this measure is sensitive to clinical
change, this is not well documented (Berth-Jones et al.,
2006).
Simplified PASI (SPASI)
The SPASI is mathematically derived from the PASI and is
meant to be easy to use (Louden et al., 2004). The SPASI
equals the sum of the average redness, thickness, and
scaling of all the psoriasis lesions, multiplied by an estimate
of total percentage body surface areas involved. Using
a simulated patient database, correlation coefficients bet-
ween the SPASI and PASI exceeded 0.90. Reliability has
not been tested. Although not formally studied, the SPASI
seems relatively insensitive to change, especially with less
extensive involvement (BSA o10%) or localized disease
(Louden et al., 2004).
Psoriasis Log-Based Area and Severity Index (PLASI) and
Psoriasis Exact Area and Severity Index (PEASI)
Derived from the PASI, the PLASI and the PEASI are intended
to provide more accurate assessment of improvement. The
PLASI uses six BSA groupings (100–46, 46–21, 21–10, 10–5,
5–2 and 2–0%) with finer partitioning for smaller extents of
BSA affected. This is supposed to reduce the error resulting
from inaccurate estimation of BSA in patients with less
extensive disease, also to increase sensitivity among patients
with mild-to-moderate disease in detecting changes in
psoriasis severity.
The PEASI uses actual BSA percentages instead of an area
score for each body area. The PEASI and PLEASI have not
been validated and are not tested for reliability. Considering
responsiveness the observed percentage change was greater
for both the PLEASI and the PEASI than with the PASI
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(Jacobson and Kimball, 2004). Most patients score below
360 on a 1200-point scale. Both DPEASI and DPLEASI
corresponded with patients’ self-assessments (Jacobson and
Kimball, 2004).
The frequency of use
In randomized-controlled trials published between 2000 and
May 2007, the PASI was used most often (126 times).
Frequently used were sum-scores of erythema, scaling and
induration, and the PGA (67 and 52 times, respectively). BSA
involvement and SAPASI were used occasionally (10 and
2 times, respectively). Several clinical severity measures were
developed recently and had not yet been cited in psoriasis
randomized-controlled trials published before May 2007.
Summary of results
Only PASS and LS-PGA scored high for ‘‘content validity’’,
because they gave more weight to induration. PGA, LS-PGA,
PEASI, PLASI, and SAPASI correlated well with the PASI,
which was used for ‘‘criterion validity’’ in the absence of
consensus on a gold standard. BSA, PASI, PGA, and LS-PGA
correlated well with other clinical psoriasis measures and
thus scored well on ‘‘construct validity’’. For ‘‘test-retest
reliability’’ and ‘‘inter-rater reliability’’ the LS-PGA, the
PGA, and the PASI scored best. Only for the SAPASI, PASS,
PEASI, and PLASI, positive information was found on respon-
siveness. Clinical relevant categorization was found for
PGA, SAPASI, and LS-PGA. The minimal important change,
however, was not defined for any of the measures. BSA and
signs were the only measures for which there are several
scales in use.
In Table 3 the number of studies evaluating the severity
measures is given. No trend could be found between the
number of articles evaluating the measures and the values
given to the quality criteria.
DISCUSSION
In this study, we showed that there are many different clinical
measures in use for psoriasis and that their number still rises.
In 2000, Naldi et al. had identified 44 psoriasis measures in
clinical trials, which had increased to 53 clinical measures in
our search. For quantitative analysis of the main psoriasis
measures, the number of eligible articles per measure varied
from 0 to 28. Table 3 enables researchers and clinicians
involved in clinical psoriasis assessment to make an
evidence-based choice for selecting an appropriate measure
based on the evaluation of the appropriate clinimetric
dimensions. None of the measures had been tested for all
of the clinimetric items. More importantly, most of them had
not been tested properly for most of the items.
Surprisingly, many of the clinical psoriasis measures that
have been developed to overcome limitations of the PASI
(SAPASI, PASS, SPASI, PEASI, and PLASI), could not exceed
the PASI on most of the clinimetric properties. Often quality
data were only available in the single article that introduced
these measures.
Criteria for objectively assessing administerability were
derived from Schmitt et al. (2007). However, none of the
included articles gave an indication of the time needed for
the assessment (although this may vary from person to
person). All remarks on administerability in the included
articles were highly subjective.
A remarkable finding in the review was the weak
correlation of HRQoL measures with the PASI, which is used
as an almost universal outcome measure in psoriasis trials.
The majority of the correlation values ranged from 0.1 to 0.3
(Kirby et al., 2000; Sampogna et al., 2004). This weak
correlation between clinical severity and HRQoL was also
seen when patients themselves assessed the clinical severity
with the SAPASI (Sampogna et al., 2004). We expected
clinical severity to correlate more with quality of life.
Especially, as we know that reductions in physical and
mental functioning because of psoriasis have found to be
similar to those reported in patients with cancer, arthritis,
hypertension, heart disease, diabetes, and depression (Rapp
et al., 1999). The discrepancy could be explained by the fact
that an objectively moderate psoriasis plaque may have a
great impact on HRQoL, if on a visible area of the body or
around the genitals. Even so, a large mild plaque may give a
high objective clinical score, but may have a low impact on
HRQoL. There is also evidence that a mismatch of low PASI
and significantly impaired HRQoL suggests comorbid depres-
sion. Especially patients with high HRQoL impairment
despite objectively mild psoriasis should be screened for
depression (Schmitt and Ford, 2007).
As severity measures and psychometric measures assess
different constructs, they should be presented as separate
scores and not summed in a single score. However, in
assessing disease severity, HRQoL scores are complementary
to the clinical severity scores. For instance, the PASI may
show significant improvement in clinical disease severity and
HRQoL measures can be used to confirm that these changes
are clinically meaningful (Feldman and Krueger, 2005).
Issues like these can only be identified using well
validated, one-dimensional measures in research and prac-
tice. For this reason, we excluded multidimensional measures
such as NPF-PS, Beer Sheva Severity Score and Dermatology
Index of Disease Severity from our systematic review.
However, most of the one-dimensional severity measures
for psoriasis, like the PASI, are in a way composite measures.
The end points of erythema, induration, scaling, and
area involvement are integrated to form a single value.
When using these measures, it should be kept in mind that
a significant change in the score does not imply that all
components necessarily trended in the same direction
(Buzney and Kimball, 2008).
A limitation of the study is, that the adapted quality criteria
for evaluating clinical psoriasis measures are not validated.
However, no validated list for evaluating validation studies of
clinical severity measures is available. The HRQoL criteria
we based our criteria on are widely accepted and used before
(Both et al., 2007). Furthermore, the used items and applied
criteria are clearly described.
Another limitation is lack of quality criteria for the inclu-
ded articles. The study results are influenced by the included
population, the assessor and the circumstances among other
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Table 4. The definitions of the clinimetric properties, grading categories, and weighted score for clinical severity
outcome measures
Property Definition Score Quality criteria
Validity
1a. Content
validity
The extent to which the type and number of scale
items of the outcome measure adequately represent
the underlying construct
A Fulfillment of all demands:
A clear description is provided of the measurement aim
The target population is described
All the concepts of disease severity are included, such as body
surface area involved, erythema, scaling and induration, and
the rating used in the clinical severity measure is elucidated
Plaque elevation is given more weight, as it is assumed to be
the most significant clinical sign of the disease
C All of the above-mentioned demands are rated positive, but
plaque elevation is not given more weight
E One or more above-mentioned demands are not fulfilled
1b. Criterion
validity
The extent to which clinical measures relate to the
PASI (only original data used)
Spearman’s rank correlation between clinical severity measure
and PASI
A rX0.7(very strong correlation)
B r=0.5–0.7 (strong correlation)
C r=0.3–0.49 (moderate correlation)
D r=0.29–0.1 (weak correlation)
E r=0 (no correlation)
1c. Construct
validity
The extent to which scores relate to other measures.
The results are shown separately for relation to
other severity measures, to symptom measures,
and to HRQoL measures (only original data used)
Overall Spearman’s rank correlations with other outcome
measures divided into (1) other clinical severity measures,
(2) symptom measures and (3) quality of life measures.
Overall Spearman’s rank correlation for each group:
A r=4 0.7 (very strong correlation)
B r=0.5–0.7 (strong correlation)
C r=0.3–0.49 (moderate correlation)
D r=0.29–0.1 (weak correlation)
E r=0 (no correlation)
Reliability
2a. Test-retest/
interpreter
reliability
Examines the influence of random error by determining
how consistent scores remain across multiple
administrations of the instrument, and can be
determined by correlating rating scores from multiple
testing sessions (only original data used)
ICC or weighted kappa calculated:
A 81–100% (substantial)
B 61–80% (moderate)
C 41–60% (fair)
D 11–40% (slight)
E 0–10%: (virtually none)
Only correlation coefficients are calculated:
D 81–100%
E 0–80%
2b Inter-rater
reliability
Examines the degree to which multiple observers agree
on the assignment of scales (only original data used)
ICC or weighted kappa calculated:
A 81–100% (substantial)
B 61–80% (moderate)
C 41–60% (fair)
D 11–40% (slight)
E 0–10%: (virtually none)
Table 4 continued on following page
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things. We had no minimum criteria for inclusion, like the
use of experienced assessors, a minimum number of patients,
an applicable population or stable circumstances. Also the
quantity of included studies per measurement is likely to
influence the grading.
CONCLUSION
The main conclusion is that there are no adequately vali-
dated clinical measures for psoriasis. As there is no supreme
measure, different measures might be ideal for different
situations and we might need all of them. When choosing a
measure, it is important to determine the most needed
features, for example, good responsiveness or sensitivity
in mild disease. It may be necessary to combine two or
more scores to satisfy all needs. For example, PASI may
not be particularly sensitive for mild disease, but it may
be outstanding for a study in which patients have severe
disease. It also provides the advantage of a large base of
studies in which it has been used. Another instrument may
have some characteristics that are better, but this may
not outweigh the benefit of being able to compare with
the existing database of studies that used PASI. For inter-
ventional studies responsiveness is important, which points
to some newer measures like the PLASI and PEASI. In
cross-sectional studies interpretability is important which
favors the PGA, SAPASI, and LS-PGA. If someone would
do a mail survey of psoriasis patients, the SAPASI is preferred
because this measure is developed for patient assessment.
If future authors want a reliable instrument, then the
LS-PGA and PASI would be best, with the PGA a close
follow-up.
Further validation studies are needed to complete the
overview of the clinimetric properties of the evaluated
measures. An item that is specifically important is the
Table 4. Continued
Property Definition Score Quality criteria
Only correlation coefficients are calculated:
D 81–100%
E 0–80%
3. Responsiveness The ability of an instrument to detect changes over
time. The instrument should be able to distinguish
clinically important change from measurement error
As this is not tested for clinical severity measures in psoriasis,
we only distinguish between:
A Positive information found on responsiveness
E Negative information found on responsiveness
4. Response
distribution
Examines whether the entire range of a scale is used
(only original data used)
A Positive information found on the usage of the entire range
of a scale
E Negative information found on the usage of the entire range
of a scale
5. Interpretability The degree to which one can assign qualitative
meaning to quantitative scores. Scores should provide
information about what (change in) score would
be clinically meaningful
A:
A Clinically relevant categorization is defined
E Clinically relevant categorization is not defined
B:
A Minimal important change is defined
E Minimal important change is not defined
6. Easy to
administer
The degree to which an outcome measure can easily
be used in clinical practice (only original data used)
A Fulfillment of all demands:
Fulfilling the rating is not time consuming (not exceeding
3min)
No extra tools (except score form) are needed
The rating is easily understandable
C Fulfilling criteria above, but fulfilling the rating takes between
3 and 7min
E Not fulfilling X1 of the above criteria
7. Uniformity The degree to which there are variations in used scales
with the same clinical severity measure
A Only one rating is used per clinical severity measure
E More than one rating is used per clinical severity measure
Criteria were adjusted from Terwee et al. (2007) and Both et al. (2007).
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definition of minimal important changes and categorizations,
for better interpretation of the results of the measures.
Furthermore, future research is needed that focuses on
responsiveness, which is an important item especially when
evaluating new therapies.
MATERIALS AND METHODS
Search strategy
To update the list of all clinical psoriasis measures a Medline search
was conducted in May 2007, using the term ‘‘psoriasis’’ combined
with common clinical severity measures to retrieve an initial list of
existing clinical outcome measures. An additional Medline search
with ‘‘psoriasis’’ and ‘‘Randomized-Controlled Trials’’ was con-
ducted limited to the years 2000–2007.
To evaluate the found measures on the quality criteria, a search
in Medline, Embase, Central and DARE was conducted, with
‘‘psoriasis’’ and an extensive validation filter created by a clinical
librarian. The specific search details are available online (see
Supplementary Table S1).
Selection
For the list of the clinical psoriasis measures all studies including
instruments that used clinical physical examination to measure
psoriasis severity were eligible. Composite, symptom and/or HRQoL
measures were excluded. We excluded direct physical measures,
such as ultrasound in this review. These measures are not generally
practical for daily use and their clinical utility is not clear. For the
quality evaluation all studies evaluating the eligible measures for
validity, reliability, responsiveness, response distribution, interpret-
ability, ease to administer or uniformity were included (Supplemen-
tary Figure S1). Two reviewers independently screened all articles on
title/abstract. Disagreements were solved by discussion. The reference
lists of these articles were screened for additional studies. Final selection
for inclusion was based on the assessment of the full-text article.
Critical appraisal
There is no format for critical appraisal of these publication types
available.
Data extraction and analyses
Two reviewers independently extracted data from the selected
articles.
We extracted all different clinical psoriasis measures used from
2000 up to May 2007, which had been done by Naldi et al. up to
2000 (Naldi et al., 2003). For evaluating the quality of the measures,
we adjusted guidelines for HRQoL instruments (Both et al., 2007;
Terwee et al., 2007). Table 4 presents the definitions of the quality
criteria and the grading categories. Each quality criterion was scored
for all the measures.
There is no consensus on a gold standard for psoriasis, although
to PASI is sometimes considered as such (Feldman et al., 1996;
Ashcroft et al., 1999; Fleischer, Jr et al., 1999; Jacobson and Kimball,
2004; Berth-Jones et al., 2006). Nevertheless, we used the PASI for
criterion validity, because it is an almost universal outcome measure
in clinical trials of antipsoriatic agents. No overall sum-scores are
given since this would assume that the contribution of the different
measurement properties to the overall quality is known and that
these properties are equally important.
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